Page last updated: 2024-09-05

sorafenib and resminostat

sorafenib has been researched along with resminostat in 2 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(resminostat)
Trials
(resminostat)
Recent Studies (post-2010) (resminostat)
6,5207305,25120619

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)resminostat (IC50)
Histone deacetylase 1Homo sapiens (human)0.46
Histone deacetylase 6Homo sapiens (human)0.072

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Ammendola, AS; Bitzer, M; Cillo, U; Dollinger, MM; Ganten, TM; Gerken, G; Giannini, EG; Hauns, B; Henning, SW; Hentsch, B; Herz, T; Holzapfel, J; Horger, M; Lauer, UM; Mais, A; Malek, NP; Montesarchio, V; Pegoraro, S; Santoro, A; Scheulen, ME; Siveke, JT; Trevisani, F; Wege, H; Wörns, MA; Zagonel, V1
Borgmann, M; Hamm, S; Hermann, F; Kallus, H; Parnitzke, U; Schrepfer, S; Streubel, G; Wulff, T1

Trials

1 trial(s) available for sorafenib and resminostat

ArticleYear
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.
    Journal of hepatology, 2016, Volume: 65, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Hydroxamic Acids; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Sulfonamides

2016

Other Studies

1 other study(ies) available for sorafenib and resminostat

ArticleYear
Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma.
    Scientific reports, 2021, 05-05, Volume: 11, Issue:1

    Topics: Animals; Antineoplastic Agents; Blood Platelets; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Therapy, Combination; Epithelial-Mesenchymal Transition; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Liver Neoplasms; Mice; Signal Transduction; Sorafenib; Sulfonamides

2021